WALVAX(SZ:300142) Xin Lang Cai Jing·2025-11-18 01:29Core Insights - Watson Bio's stock declined by 1.25% on November 17, with a trading volume of 511 million yuan, indicating a negative market sentiment towards the company [1] - The company experienced a net financing outflow of 27.51 million yuan on the same day, with total financing and securities balance reaching 1.952 billion yuan [1][2] - For the first nine months of 2025, Watson Bio reported a revenue of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit of 163 million yuan, down 36.24% compared to the previous year [2] Financing and Trading Activity - On November 17, Watson Bio had a financing buy-in of 53.02 million yuan, with a current financing balance of 1.94 billion yuan, representing 9.63% of its market capitalization [1] - The financing balance is below the 50th percentile level over the past year, indicating a relatively low level of leverage [1] - In terms of securities lending, Watson Bio repaid 9,200 shares and sold 63,300 shares on November 17, with a total selling amount of approximately 796,900 yuan [1] Shareholder and Institutional Holdings - As of September 30, 2025, Watson Bio had 114,000 shareholders, a decrease of 2.75% from the previous period, while the average number of circulating shares per shareholder increased by 2.83% to 13,643 shares [2] - The top institutional shareholder, E Fund's ChiNext ETF, held 34.47 million shares, down by 5.80 million shares from the previous period [2] - Other notable institutional shareholders include Southern CSI 500 ETF and China Merchants National Bio-Medical Index A, both of which also saw a reduction in their holdings [2]